Strongbridge Biopharma Profile

4.35
USD 0.05  1.14%
23%
32%

Strongbridge Biopharma exotic insider transaction detected

Strongbridge Biopharma plc insider trading alert for general transaction of stock option (right to buy) by Stephen Long, Chief Legal Officer, on September 14, 2018. This event was filed by Strongbridge Biopharma Pl with SEC on 2018-01-02. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Strongbridge Biopharma Summary

Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in 900 Northbrook Drive and employs 66 people. The company currently falls under 'Small-Cap' category with current market capitalization of 261.58 M. Strongbridge Biopharma plc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 46.71 M outstanding shares of which 416.96 K shares are at this time shorted by private and institutional investors with about 1.28 trading days to cover. Strongbridge Biopharma plc currently holds about 85.51 M in cash with (52.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Check Strongbridge Biopharma Probability Of Bankruptcy

Ownership Allocation (%)

Strongbridge Biopharma Target Price Odds Analysis

Odds Below 4.35HorizonTargetOdds Above 4.35
15.16%30 days 4.35 84.76%
Based on normal probability distribution, the odds of Strongbridge Biopharma to move above current price in 30 days from now is about 84.76% (This Strongbridge Biopharma plc probability density function shows the probability of Strongbridge Biopharma Stock to fall within a particular range of prices over 30 days) .

Strongbridge Biopharma Top Holders

Strongbridge Biopharma Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Caxton CorpCommon Shares5.4 M32.4 M
Lyon Street Capital LlcCommon Shares4.6 M27.4 M
View Strongbridge Biopharma Diagnostics

Strongbridge Biopharma Risk Profiles

Strongbridge Biopharma Key Fundamentals

Strongbridge Biopharma Against Markets

Strongbridge Biopharma Current Ratings

Strongbridge Biopharma plc 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
50 
Equity ratings for Strongbridge Biopharma plc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania. Strongbridge Biopharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 66 people. more
NameStrongbridge Biopharma plc
CEO and President and DirectorMatthew PaulsView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address900 Northbrook Drive
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.strongbridgebio.com
Phone610 254 9200
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestJuly 31, 2018

Strongbridge Biopharma Directors

Strongbridge Biopharma Corporate Directors

Also please take a look at World Market Map. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.
Search macroaxis.com